Drug profile · INN
efalizumab
RAPTIVA
efalizumab (RAPTIVA) is a integrin alpha-l/beta-2 (lfa-1) inhibitor.
EMA: withdrawn Antineoplastic and immunomodulating agents (L04) L04AA21
Patents linked 0
Pipeline programs 0
News articles 0
Drug details — efalizumab
- Class
- Antineoplastic and immunomodulating agents (L04)
- Route
- —
- Patents
- 0
- Programs
- 0
- Data quality
- 0.83
Quick answer
efalizumab (RAPTIVA) is a integrin alpha-l/beta-2 (lfa-1) inhibitor.
Key facts
INN efalizumab
Brand RAPTIVA
Mechanism Integrin alpha-L/beta-2 (LFA-1) inhibitor
Target Integrin alpha-L/beta-2 (LFA-1)
Therapeutic class Antineoplastic and immunomodulating agents (L04)
ATC code L04AA21
Mechanism of action
Integrin alpha-L/beta-2 (LFA-1) inhibitor
Primary target: Integrin alpha-L/beta-2 (LFA-1)
Approval history
| Authority | Status | Date |
|---|---|---|
| EMA | withdrawn | — |
Related & competitor drugs
Frequently asked questions
What is efalizumab?
efalizumab (RAPTIVA) is a integrin alpha-l/beta-2 (lfa-1) inhibitor.
What is the brand name for efalizumab?
RAPTIVA is a marketed brand name for efalizumab. Check FDA Drugs@FDA for the current US label holder and prescribing information.